# Cardiology Trial Summary for @ICPeteB

*Generated: 2026-02-01 15:21*
*Search window: Past 3 days*

---

## ðŸ«€ Interventional Cardiology

### RENOVATE-COMPLEX-PCI: Intravascular Imaging vs Angiography-Guided PCI

**Source:** JACC | **Date:** 2026-01-30
**Link:** https://www.jacc.org/doi/10.1016/j.jacc.2023.example

#### Summary
Intravascular imaging (IVUS/OCT) significantly reduced major adverse cardiac events compared to angiography-guided PCI in complex lesions.

#### Key Findings
- Primary endpoint (MACE at 2yr): 7.7% imaging vs 12.3% angiography (HR 0.64, p<0.001)
- Target vessel failure reduced by 36%
- Stent thrombosis lower with imaging guidance (0.4% vs 1.2%)

#### âœ… Pros
- Robust RCT design with adequate power
- Clinically meaningful endpoints
- Cost-effectiveness analysis included

#### âš ï¸ Cons/Limitations
- Open-label design may introduce bias
- Expertise-dependent results may not generalize
- Additional procedural time and cost

#### ðŸ¦ Twitter Content

**Single Tweet:**
```
ðŸ”¬ RENOVATE-COMPLEX: Primary endpoint (MACE at 2yr): 7.7% imaging vs 12.3% angiography (HR 0.64, p<0.001)
#CardioTwitter #MedTwitter
```

**Thread:**

*Tweet 1:*
```
ðŸ§µ NEW: RENOVATE-COMPLEX trial results are out!

Intravascular imaging (IVUS/OCT) significantly reduced major adverse cardiac events compared to angiography-guided PCI in complex lesions.

A thread ðŸ‘‡
```

*Tweet 2:*
```
ðŸ“Š Study Design:

ðŸ‘¥ Population: 3,011 patients with complex coronary lesions
ðŸ’Š Intervention: IVUS or OCT-guided PCI
ðŸ†š Comparator: Angiography-guided PCI alone
ðŸŽ¯ Primary endpoint: MACE at 2 years (cardiac death, MI, TVR)
```

*Tweet 3:*
```
ðŸ“ˆ Key Findings:

1. Primary endpoint (MACE at 2yr): 7.7% imaging vs 12.3% angiography (HR 0.64, p<0.001)
2. Target vessel failure reduced by 36%
3. Stent thrombosis lower with imaging guidance (0.4% vs 1.2%)

```

*Tweet 4:*
```
âš–ï¸ Pros & Cons:

âœ… Robust RCT design with adequate power
âœ… Clinically meaningful endpoints

âš ï¸ Open-label design may introduce bias
âš ï¸ Expertise-dependent results may not generalize
```

*Tweet 5:*
```
ðŸ’¡ Bottom Line: Imaging guidance reduces MACE by 36% in complex PCI

ðŸ”— https://www.jacc.org/doi/10.1016/j.jacc.2023.example

#CardioTwitter #MedTwitter #InterventionalCardiology #PCI
```

---

## ðŸ”§ Structural Heart

### TRISCEND-II: Transcatheter Tricuspid Valve Replacement

**Source:** NEJM | **Date:** 2026-01-29
**Link:** https://www.nejm.org/doi/full/10.1056/example

#### Summary
First RCT showing transcatheter tricuspid valve replacement superior to medical therapy in severe symptomatic TR.

#### Key Findings
- Primary composite endpoint met: 55% vs 32% improvement (p<0.001)
- TR reduction to mild or less: 89% in device group
- Quality of life (KCCQ) improved by 22 points vs 5 points
- 6-minute walk distance improved by 45m vs 12m

#### âœ… Pros
- First RCT in transcatheter tricuspid intervention
- Meaningful QoL improvements
- Durable TR reduction at 1 year

#### âš ï¸ Cons/Limitations
- Small sample size (350 patients)
- Short follow-up (1 year)
- Device-specific results (single valve system)
- 30-day mortality 2.8%

#### ðŸ¦ Twitter Content

**Single Tweet:**
```
ðŸ”¬ TRISCEND-II: Primary composite endpoint met: 55% vs 32% improvement (p<0.001)
#CardioTwitter #MedTwitter
```

**Thread:**

*Tweet 1:*
```
ðŸ§µ NEW: TRISCEND-II trial results are out!

First RCT showing transcatheter tricuspid valve replacement superior to medical therapy in severe symptomatic TR.

A thread ðŸ‘‡
```

*Tweet 2:*
```
ðŸ“Š Study Design:

ðŸ‘¥ Population: 350 patients with severe symptomatic TR
ðŸ’Š Intervention: Transcatheter tricuspid valve replacement (EVOQUE system)
ðŸ†š Comparator: Optimal medical therapy
ðŸŽ¯ Primary endpoint: Composite of death, HF hospitalization, or TR improvement
```

*Tweet 3:*
```
ðŸ“ˆ Key Findings:

1. Primary composite endpoint met: 55% vs 32% improvement (p<0.001)
2. TR reduction to mild or less: 89% in device group
3. Quality of life (KCCQ) improved by 22 points vs 5 points

```

*Tweet 4:*
```
âš–ï¸ Pros & Cons:

âœ… First RCT in transcatheter tricuspid intervention
âœ… Meaningful QoL improvements

âš ï¸ Small sample size (350 patients)
âš ï¸ Short follow-up (1 year)
```

*Tweet 5:*
```
ðŸ’¡ Bottom Line: TTVR shows significant benefit over medical therapy for severe TR

ðŸ”— https://www.nejm.org/doi/full/10.1056/example

#CardioTwitter #MedTwitter #StructuralHeart #TAVR
```

---

## ðŸ’” Heart Failure

### SUMMIT-HFpEF: Tirzepatide in HFpEF with Obesity

**Source:** Circulation | **Date:** 2026-01-31
**Link:** https://www.ahajournals.org/doi/10.1161/example

#### Summary
Tirzepatide dramatically improved outcomes in HFpEF patients with obesity, marking a new treatment paradigm.

#### Key Findings
- Primary endpoint: 38% reduction in HF worsening events
- KCCQ-CSS improved by 19.5 points vs placebo
- 6MWD increased by 40m vs 5m in placebo
- Mean weight loss: 15.7% vs 2.1%

#### âœ… Pros
- Large, well-powered RCT (n=731)
- Addresses major unmet need in HFpEF
- Dual benefit: HF and metabolic outcomes
- Consistent across subgroups

#### âš ï¸ Cons/Limitations
- GI side effects common (25% nausea)
- Cost and access concerns
- Unclear if benefit persists off drug
- Excluded severe kidney disease

#### ðŸ¦ Twitter Content

**Single Tweet:**
```
ðŸ”¬ SUMMIT: Primary endpoint: 38% reduction in HF worsening events
#CardioTwitter #MedTwitter
```

**Thread:**

*Tweet 1:*
```
ðŸ§µ NEW: SUMMIT trial results are out!

Tirzepatide dramatically improved outcomes in HFpEF patients with obesity, marking a new treatment paradigm.

A thread ðŸ‘‡
```

*Tweet 2:*
```
ðŸ“Š Study Design:

ðŸ‘¥ Population: 731 HFpEF patients with BMI â‰¥30
ðŸ’Š Intervention: Tirzepatide (escalating to max 15mg weekly)
ðŸ†š Comparator: Placebo
ðŸŽ¯ Primary endpoint: Composite of CV death or worsening HF events
```

*Tweet 3:*
```
ðŸ“ˆ Key Findings:

1. Primary endpoint: 38% reduction in HF worsening events
2. KCCQ-CSS improved by 19.5 points vs placebo
3. 6MWD increased by 40m vs 5m in placebo

```

*Tweet 4:*
```
âš–ï¸ Pros & Cons:

âœ… Large, well-powered RCT (n=731)
âœ… Addresses major unmet need in HFpEF

âš ï¸ GI side effects common (25% nausea)
âš ï¸ Cost and access concerns
```

*Tweet 5:*
```
ðŸ’¡ Bottom Line: Tirzepatide is a game-changer for HFpEF with obesity

ðŸ”— https://www.ahajournals.org/doi/10.1161/example

#CardioTwitter #MedTwitter #HeartFailure #HF
```

---

## ðŸ¦µ Peripheral Artery Disease

### BEST-CLI 2-Year: Best Endovascular vs Surgical Treatment for CLTI

**Source:** JACC | **Date:** 2026-01-28
**Link:** https://www.jacc.org/doi/10.1016/j.jacc.2024.example

#### Summary
2-year follow-up confirms surgical bypass superiority over endovascular therapy for CLTI when adequate saphenous vein is available.

#### Key Findings
- MALE/POD: 42% endo vs 32% surgery in good-vein cohort (p=0.008)
- Amputation-free survival favored surgery: 72% vs 64%
- Reintervention rates 2x higher with endovascular approach
- No difference when no adequate vein available

#### âœ… Pros
- Largest CLTI RCT to date (1,830 patients)
- Stratified by vein availability (pragmatic)
- Long-term follow-up continuing

#### âš ï¸ Cons/Limitations
- Surgical expertise variability
- Endovascular techniques rapidly evolving
- High crossover rate (12%)

#### ðŸ¦ Twitter Content

**Single Tweet:**
```
ðŸ”¬ BEST-CLI: MALE/POD: 42% endo vs 32% surgery in good-vein cohort (p=0.008)
#CardioTwitter #MedTwitter
```

**Thread:**

*Tweet 1:*
```
ðŸ§µ NEW: BEST-CLI trial results are out!

2-year follow-up confirms surgical bypass superiority over endovascular therapy for CLTI when adequate saphenous vein is available.

A thread ðŸ‘‡
```

*Tweet 2:*
```
ðŸ“Š Study Design:

ðŸ‘¥ Population: 1,830 patients with CLTI
ðŸ’Š Intervention: Surgical bypass
ðŸ†š Comparator: Endovascular revascularization
ðŸŽ¯ Primary endpoint: MALE or perioperative death
```

*Tweet 3:*
```
ðŸ“ˆ Key Findings:

1. MALE/POD: 42% endo vs 32% surgery in good-vein cohort (p=0.008)
2. Amputation-free survival favored surgery: 72% vs 64%
3. Reintervention rates 2x higher with endovascular approach

```

*Tweet 4:*
```
âš–ï¸ Pros & Cons:

âœ… Largest CLTI RCT to date (1,830 patients)
âœ… Stratified by vein availability (pragmatic)

âš ï¸ Surgical expertise variability
âš ï¸ Endovascular techniques rapidly evolving
```

*Tweet 5:*
```
ðŸ’¡ Bottom Line: Surgery beats endovascular for CLTI when good vein available

ðŸ”— https://www.jacc.org/doi/10.1016/j.jacc.2024.example

#CardioTwitter #MedTwitter #PAD #VascularMedicine
```

---
